down arrow

Medifast, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US58470H1014
USD
10.86
-0.15 (-1.36%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.7211.09

52 Week

10.3621.98
Valuation
Technical
Day's Volume

CASH

312.96 k

Shareholding (Mar 2025)

FII

9.96%

Held by 91 FIIs

DII

18.18%

Held by 74 DIIs

Promoter

0.16%

How big is Medifast, Inc.?

22-Jun-2025

As of Jun 18, Medifast, Inc. has a market capitalization of 148.27 million and reported net sales of 543.45 million with a net profit of -6.99 million over the latest four quarters. Shareholder's funds total 210.11 million, and total assets are 293.23 million.

As of Jun 18, Medifast, Inc. has a market capitalization of 148.27 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 543.45 million, while the sum of net profit for the same period is -6.99 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 210.11 million, and the total assets are reported at 293.23 million.

Read More

What does Medifast, Inc. do?

22-Jun-2025

Medifast, Inc. produces and sells weight loss and healthy living products, operating in the micro-cap market with a recent net sales of $116 million and a net profit of -$1 million. The company has a market cap of $148.27 million and does not pay dividends.

Overview: <BR>Medifast, Inc. produces, distributes, and sells weight loss, weight management, and healthy living products within the Miscellaneous industry and operates in the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 116 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 148.27 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.75 <BR>Return on Equity: -0.84% <BR>Price to Book: 0.70<BR><BR>Contact Details: <BR>Address: 11445 Cronhill Dr, OWINGS MILLS MD: 21117-2270 <BR>Tel: 1 732 7640619 <BR>Fax: 1 410 5818070 <BR>Website: https://www.medifast1.com

Read More

Who are in the management team of Medifast, Inc.?

22-Jun-2025

As of March 2022, the management team of Medifast, Inc. includes Executive Chairman and CEO Daniel Chard, Lead Independent Director Jeffrey Brown, and Independent Directors Kevin Byrnes, Constance Hallquist, Michael Hoer, and Scott Schlackman. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Medifast, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Chard, who serves as the Executive Chairman of the Board and Chief Executive Officer.<BR>- Mr. Jeffrey Brown, who is the Lead Independent Director.<BR>- Mr. Kevin Byrnes, an Independent Director.<BR>- Ms. Constance Hallquist, an Independent Director.<BR>- Mr. Michael Hoer, an Independent Director.<BR>- Mr. Scott Schlackman, an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Read More

Is Medifast, Inc. overvalued or undervalued?

20-Sep-2025

As of August 7, 2025, Medifast, Inc. is considered undervalued with a valuation grade shift to attractive, despite negative earnings metrics and a year-to-date return of -17.31%, compared to the S&P 500's 12.22%, while its Price to Book Value is 0.66 and EV to EBIT ratio is 2.98, indicating relative attractiveness against peers with lower P/E ratios.

As of 7 August 2025, the valuation grade for Medifast, Inc. has moved from expensive to attractive, indicating a shift in perception regarding its valuation. The company appears to be undervalued, particularly given its Price to Book Value of 0.66 and an EV to EBIT ratio of 2.98, despite the challenges reflected in its negative earnings metrics. <BR><BR>In comparison to its peers, Medifast's P/E ratio stands at 62.80, while Thoughtworks Holding, Inc. and Chegg, Inc. exhibit significantly lower P/E ratios of -25.45 and -22.62, respectively, highlighting the relative attractiveness of Medifast within this group. Additionally, the company has underperformed against the S&P 500, with a year-to-date return of -17.31% compared to the index's 12.22%, and a staggering -91.61% return over the past five years, suggesting that while the stock may be undervalued, it has faced significant headwinds in the market.

Read More

Is Medifast, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Medifast, Inc. shows a mildly bearish technical trend, with daily moving averages indicating bearishness despite some positive momentum from weekly and monthly MACD indicators, and it has significantly underperformed the S&P 500 year-to-date and over the past year.

As of 2 September 2025, the technical trend for Medifast, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the daily moving averages indicate a mildly bearish stance, and the Bollinger Bands show a mixed signal with a bullish weekly and mildly bearish monthly outlook. The Dow Theory reflects a mildly bullish weekly trend but no trend on the monthly basis. <BR><BR>In terms of performance, Medifast has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -17.31% compared to the S&P 500's 12.22%, and a 1-year return of -22.58% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the daily moving averages and mixed signals from other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a fall in PBT of -258.16%, the company declared Very Negative results in Jun 25

  • The company has declared negative results for the last 12 consecutive quarters
  • NET PROFIT(HY) At USD 0.33 MM has Grown at -87.43%
  • OPERATING CASH FLOW(Y) Lowest at USD 4.15 MM
  • NET SALES(Q) Lowest at USD 105.56 MM
2

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 152 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.73

stock-summary
Return on Equity

1.12%

stock-summary
Price to Book

0.70

Revenue and Profits:
Net Sales:
106 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.59%
0%
-21.59%
6 Months
-19.79%
0%
-19.79%
1 Year
-44.98%
0%
-44.98%
2 Years
-84.43%
0%
-84.43%
3 Years
-91.03%
0%
-91.03%
4 Years
-94.54%
0%
-94.54%
5 Years
-94.7%
0%
-94.7%

Medifast, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Medifast, Inc. Hits 52-Week Low at $11.25 Amid Ongoing Struggles

Medifast, Inc. Hits 52-Week Low at $11.25 Amid Ongoing Struggles

Medifast, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant stock price decline. The company reported a sharp drop in net profit and operating cash flow, alongside the lowest net sales in recent history. Despite maintaining a high return on equity, it has faced negative results for 12 consecutive quarters.

Read More
Medifast, Inc. Experiences Revision in Its Stock Evaluation Amidst Financial Challenges

Medifast, Inc. Experiences Revision in Its Stock Evaluation Amidst Financial Challenges

Medifast, Inc. has experienced a valuation adjustment amid challenging financial metrics, including a negative return on equity and significant operational hurdles. Compared to peers, its valuation ratios highlight broader industry difficulties. Year-to-date returns are down substantially, reflecting competitive pressures and operational challenges in the current market environment.

Read More
Medifast, Inc. Experiences Valuation Adjustment Amidst Challenging Market Conditions

Medifast, Inc. Experiences Valuation Adjustment Amidst Challenging Market Conditions

Medifast, Inc. has recently adjusted its valuation amid ongoing financial challenges, with a notable decline in its annual return. Key metrics indicate a low price-to-book value and negative performance indicators. Compared to peers, Medifast's valuation appears more favorable, suggesting a complex industry positioning for investors to consider.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-8.74%
EBIT Growth (5y)
-64.79%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.75
Sales to Capital Employed (avg)
4.56
Tax Ratio
3.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
184.68%
ROE (avg)
54.42%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.66
EV to EBIT
2.98
EV to EBITDA
-1.70
EV to Capital Employed
-0.36
EV to Sales
-0.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-0.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 64 Schemes (71.61%)

Foreign Institutions

Held by 91 Foreign Institutions (9.96%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -8.73% vs -2.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 412.50% vs -200.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.60",
          "val2": "115.70",
          "chgp": "-8.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.00",
          "val2": "2.00",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.60",
          "val2": "0.60",
          "chgp": "333.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.50",
          "val2": "-0.80",
          "chgp": "412.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10.10%",
          "val2": "-10.90%",
          "chgp": "0.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -43.80% vs -32.94% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -97.89% vs -30.78% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "602.50",
          "val2": "1,072.10",
          "chgp": "-43.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "20.30",
          "val2": "144.10",
          "chgp": "-85.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.10",
          "val2": "99.40",
          "chgp": "-97.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "4.80%",
          "val2": "117.90%",
          "chgp": "-11.31%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
105.60
115.70
-8.73%
Operating Profit (PBDIT) excl Other Income
3.00
2.00
50.00%
Interest
0.00
0.00
Exceptional Items
2.60
0.60
333.33%
Consolidate Net Profit
2.50
-0.80
412.50%
Operating Profit Margin (Excl OI)
-10.10%
-10.90%
0.08%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -8.73% vs -2.77% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 412.50% vs -200.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
602.50
1,072.10
-43.80%
Operating Profit (PBDIT) excl Other Income
20.30
144.10
-85.91%
Interest
0.00
0.00
Exceptional Items
-4.10
0.00
Consolidate Net Profit
2.10
99.40
-97.89%
Operating Profit Margin (Excl OI)
4.80%
117.90%
-11.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -43.80% vs -32.94% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -97.89% vs -30.78% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Medifast, Inc. stock-summary
stock-summary
Medifast, Inc.
Miscellaneous
Medifast, Inc. produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins. Its business units include Optavia, Medifast Direct, Franchise Medifast Weight Control Centers (MWCC) and Medifast Wholesale. Optavia is a personal coaching division of the Company that consists of Optavia Coaches, who provides coaching and support to clients utilizing the Optavia platform. Medifast Direct is its direct-to-consumer business unit that allows customers to order Medifast products directly through its Website or its in-house call center. The MWCC business unit sells product through franchise and reseller locations, which offers structured programs and a team of professionals to help customers achieve weight-loss and weight-management success at center locations.
Company Coordinates stock-summary
Company Details
11445 Cronhill Dr , OWINGS MILLS MD : 21117-2270
stock-summary
Tel: 1 732 7640619
stock-summary
https://www.medifast1.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."